Abstract
Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a life-threatening disease, especially in elderly individuals and those with comorbidities. The predominant clinical manifestation of COVID-19 is respiratory dysfunction, while neurological presentations are increasingly being recognized. SARS-CoV-2 invades host cells primarily via attachment of the spike protein to the angiotensin-converting enzyme 2 (ACE2) receptor expressed on cell membranes. Patients with Alzheimer’s disease (AD) are more susceptible to SARS-CoV-2 infection and prone to severe clinical outcomes. Recent studies have revealed some common risk factors for AD and COVID-19. An understanding of the association between COVID-19 and AD and the potential related mechanisms may lead to the development of novel approaches to treating both diseases. It is important to understand the mechanisms by which SARS-CoV-2 invades the central nervous system (CNS) and the associations and potential shared factors between COVID-19 and AD.
Keywords: COVID-19; Alzheimer’s disease; correlation; mechanism of action
References
- Hashemi Fallah., et al. "A Comprehensive Health Effects Assessment of the Use of Sanitizers and Disinfectants during COVID-19 Pandemic: A Global Survey (preprint)". (2022).
- Harfouch RM. "Antiviral Effects of Propolis against SARS-COV 2". Int J Clin Med Imaging (2022).
- Harfouch RM., et al. "Therapeutic approaches for covid 19: Challenges and successes". Annals of Clinical and Analytical Medicine (2021): 228-233.
- Alhouri Ali., et al. "Possible side effects of using detergents during the Covid19 pandemic in Syria". Ann. Clin. Cases 1.4 (2020): 1023.
- Harfouch Rim M. "Cytokine Storm syndrome in COVID-19 patients: Characteristics And diagnosis". Journal of Clinical Epidemiology & Toxicology 2.4 (2021): 1-3.
- Harfouch RM., et al. "Epidemiology of COVID-19 in the most pandemic Countries: A review article”. Acad. J. Biotechnol 9.1 (2021): 021-027.
- Harfouch Rim. "Multiple organs failure in COVID-19 patients". Authorea Preprints (2022).
- Desforges M., et al. “Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system?” Viruses 12.1 (2019).
- Harfouch Rim. "Effect of SARS-COV2 virus on nervous system and mental health". Authorea Preprints (2022).
- Matschke J., et al. “Neuropathology of patients with COVID-19 in Germany: a post-mortem case series”. Lancet Neurol 19.11 (2020): 919-29.
- Jarius S., et al. “Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients”. J Neuroinflammation 19.1 (2022): 19.
- Coolen T., et al. “Early postmortem brain MRI findings in COVID-19 non-survivors”. Neurology 95.14 (2020): e2016-27.
- Thakur KT., et al. “COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital”. Brain 144 (2021): 2696-2708.
- Lou JJ., et al. “Neuropathology of COVID-19 (neuro-COVID): clinicopathological update”. Free Neuropathol 2 (2021): 2.
- Jiang T., et al. “Angiotensin-(1-7) is reduced and inversely correlates with tau hyperphosphorylation in animal models of Alzheimer's disease”. Mol Neurobiol 53 (2016): 2489-2497.
- Kehoe PG., et al. “Angiotensin-converting enzyme 2 is reduced in Alzheimer's disease in association with increasing amyloid-beta and tau pathology”. Alzheimers Res Ther 8 (2016): 50.
- Leng F and Edison P. “Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?”. Nat Rev Neurol 17.3 (2021): 157-72.
- Abate G, Memo M and Uberti D. “Impact of COVID-19 on Alzheimer’s disease risk: viewpoint for research action”. Healthcare (2020).
- Wang WY., et al. “Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease”. Ann Transl Med 3.10 (2015): 136.
- Chen F., et al. “The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms”. Transl Neurodegener (2022).